Highlights Gossamer Bio, Inc.

Equities

GOSS

US38341P1021

Market Closed - Nasdaq Other stock markets 01:30:00 14/05/2024 am IST			5-day change	1st Jan Change
0.72 ^USD	-3.00%		-7.78%	-21.10%

07/05	Gossamer Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
06/05	Chiesi Farmaceutici S.P.A Gossamer Bio, Inc Announces Transformative Global Collaboration to Develop and Commercialize Seralutinib in Pulmonary Arterial Hypertension and Other Respiratory Indications	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Gossamer Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05	CI
Chiesi Farmaceutici S.P.A Gossamer Bio, Inc Announces Transformative Global Collaboration to Develop and Commercialize Seralutinib in Pulmonary Arterial Hypertension and Other Respiratory Indications	06/05	CI
Gossamer Bio and Chiesi Group to collaborate for blood pressure treatment	06/05	RE
Gossamer Bio Announces Publication of Torrey Phase 2 Results in the Lancet Respiratory Medicine	03/05	CI
Gossamer Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	05/03	CI
Gossamer Bio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	05/03	CI
Gossamer Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11	CI
Gossamer Bio, Inc. to Present Results of TORREY FRI Sub- Study At the European Respiratory Society International Congress 2023	07/23/07	CI
Gossamer Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	09/23/09	CI
Gossamer Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	10/23/10	CI
Gossamer Bio Inc. Announces FDA has Placed a Partial Clinical Hold on All Trials of GB5121 in Response to Serious Adverse Events	04/23/04	CI
GOSSAMER BIO, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	17/23/17	AQ
Gossamer Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	17/23/17	CI
Gossamer Bio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	17/23/17	CI
Gossamer Bio, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	17/23/17	CI
Gossamer Bio, Inc. Announces Seralutinib Meets Primary Endpoint in Phase 2 Torrey Study in PAH	06/22/06	CI
GOSSAMER BIO, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	04/22/04	AQ
Gossamer Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	04/22/04	CI
GOSSAMER BIO, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	10/22/10	AQ
Gossamer Bio Q2 Loss Narrows	09/22/09	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Gossamer Bio, Inc.

Equities

GOSS

US38341P1021

Highlights

Filters